{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:31:22Z","timestamp":1788305482442,"version":"build-2803163510"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,12,22]],"date-time":"2015-12-22T00:00:00Z","timestamp":1450742400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Pain Headache Rep"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s11916-015-0536-6","type":"journal-article","created":{"date-parts":[[2015,12,22]],"date-time":"2015-12-22T11:35:46Z","timestamp":1450784146000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Prophylactic Drug Treatment of Migraine in Children and Adolescents: An Update"],"prefix":"10.1007","volume":"20","author":[{"given":"J\u00e1nos","family":"Tajti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9lia","family":"Szok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anett","family":"Cs\u00e1ti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"V\u00e9csei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,22]]},"reference":[{"key":"536_CR1","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1212\/01.WNL.0000147332.41993.90","volume":"63","author":"D Lewis","year":"2004","unstructured":"Lewis D, Ashwal S, Hershey A, Hirtz D, Yonker M, Silberstein S, et al. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology. 2004;63:2215\u201324.","journal-title":"Neurology"},{"key":"536_CR2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1146\/annurev-physiol-030212-183717","volume":"75","author":"D Pietrobon","year":"2013","unstructured":"Pietrobon D, Moskowitz MA. Pathophysiology of migraine. Annu Rev Physiol. 2013;75:365\u201391. An excellent review of the pathomechanism of migraine.","journal-title":"Annu Rev Physiol"},{"key":"536_CR3","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1177\/0333102413485658","volume":"33","author":"Headache Classification Committee of the International Headache S","year":"2013","unstructured":"Headache Classification Committee of the International Headache S. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629\u2013808.","journal-title":"Cephalalgia"},{"key":"536_CR4","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1177\/0883073813504459","volume":"29","author":"KC Teixeira","year":"2014","unstructured":"Teixeira KC, Montenegro MA, Guerreiro MM. Migraine equivalents in childhood. J Child Neurol. 2014;29:1366\u20139.","journal-title":"J Child Neurol"},{"key":"536_CR5","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1212\/01.WNL.0000137039.08724.18","volume":"63","author":"ME Bigal","year":"2004","unstructured":"Bigal ME, Lipton RB, Tepper SJ, Rapoport AM, Sheftell FD. Primary chronic daily headache and its subtypes in adolescents and adults. Neurology. 2004;63:843\u20137.","journal-title":"Neurology"},{"key":"536_CR6","author":"MM Ernst","year":"2015","unstructured":"Ernst MM, O'Brien HL, Powers SW. Cognitive-behavioral therapy: how medical providers can increase patient and family openness and access to evidence-based multimodal therapy for pediatric migraine. Headache. 2015. doi: 10.1111\/head.12605 .","journal-title":"Headache"},{"key":"536_CR7","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s11916-014-0422-7","volume":"18","author":"J Kacperski","year":"2014","unstructured":"Kacperski J, Hershey AD. Preventive drugs in childhood and adolescent migraine. Curr Pain Headache Rep. 2014;18:422. Novel findings concerning the potential options of the preventive treatment of pediatric migraine.","journal-title":"Curr Pain Headache Rep"},{"key":"536_CR8","unstructured":"Barnes NP. Migraine headache in children. BMJ Clin Evid. 2015;2015."},{"key":"536_CR9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/head.12253","volume":"54","author":"DC Sheridan","year":"2014","unstructured":"Sheridan DC, Spiro DM, Meckler GD. Pediatric migraine: abortive management in the emergency department. Headache. 2014;54:235\u201345.","journal-title":"Headache"},{"key":"536_CR10","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s11916-013-0402-3","volume":"18","author":"CB Oakley","year":"2014","unstructured":"Oakley CB, Kossoff EH. Migraine and epilepsy in the pediatric population. Curr Pain Headache Rep. 2014;18:402.","journal-title":"Curr Pain Headache Rep"},{"key":"536_CR11","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/head.12038","volume":"53","author":"KR Merikangas","year":"2013","unstructured":"Merikangas KR. Contributions of epidemiology to our understanding of migraine. Headache. 2013;53:230\u201346.","journal-title":"Headache"},{"key":"536_CR12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.pharmthera.2012.08.011","volume":"136","author":"L Edvinsson","year":"2012","unstructured":"Edvinsson L, Villalon CM, MaassenVanDenBrink A. Basic mechanisms of migraine and its acute treatment. Pharmacol Ther. 2012;136:319\u201333.","journal-title":"Pharmacol Ther"},{"key":"536_CR13","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00702-010-0515-3","volume":"118","author":"J Tajti","year":"2011","unstructured":"Tajti J, Pardutz A, Vamos E, Tuka B, Kuris A, Bohar Z, et al. Migraine is a neuronal disease. J Neural Transm. 2011;118:511\u201324.","journal-title":"J Neural Transm"},{"key":"536_CR14","first-page":"389","volume":"59","author":"H Varga","year":"2006","unstructured":"Varga H, Pardutz A, Tajti J, Vecsei L, Schoenen J. The modulatory effect of estrogen on the caudal trigeminal nucleus of the rat in an animal model of migraine. Ideggyogy Sz. 2006;59:389\u201395.","journal-title":"Ideggyogy Sz"},{"key":"536_CR15","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/brain\/awu014","volume":"137","author":"L Vecsei","year":"2014","unstructured":"Vecsei L, Tuka B, Tajti J. Role of PACAP in migraine headaches. Brain. 2014;137:650\u20131.","journal-title":"Brain"},{"key":"536_CR16","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1517\/17425255.2014.963554","volume":"10","author":"J Tajti","year":"2014","unstructured":"Tajti J, Csati A, Vecsei L. Novel strategies for the treatment of migraine attacks via the CGRP, serotonin, dopamine, PAC1, and NMDA receptors. Expert Opin Drug Metab Toxicol. 2014;10:1509\u201320.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"536_CR17","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1517\/14656566.9.15.2565","volume":"9","author":"S Evers","year":"2008","unstructured":"Evers S. Treatment of migraine with prophylactic drugs. Expert Opin Pharmacother. 2008;9:2565\u201373.","journal-title":"Expert Opin Pharmacother"},{"key":"536_CR18","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1468-1331.2009.02748.x","volume":"16","author":"S Evers","year":"2009","unstructured":"Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, et al. EFNS guideline on the drug treatment of migraine\u2014revised report of an EFNS task force. Eur J Neurol. 2009;16:968\u201381.","journal-title":"Eur J Neurol"},{"key":"536_CR19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.npep.2015.03.006","volume":"52","author":"J Tajti","year":"2015","unstructured":"Tajti J, Szok D, Majlath Z, Tuka B, Csati A, Vecsei L. Migraine and neuropeptides. Neuropeptides. 2015;52:19\u201330.","journal-title":"Neuropeptides"},{"key":"536_CR20","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1517\/14740338.2015.1014797","volume":"14","author":"L Vecsei","year":"2015","unstructured":"Vecsei L, Majlath Z, Szok D, Csati A, Tajti J. Drug safety and tolerability in prophylactic migraine treatment. Expert Opin Drug Saf. 2015;14:667\u201381.","journal-title":"Expert Opin Drug Saf"},{"key":"536_CR21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40272-015-0125-5","volume":"17","author":"J Kacperski","year":"2015","unstructured":"Kacperski J. Prophylaxis of migraine in children and adolescents. Paediatr Drugs. 2015;17:217\u201326. A paper summarizing all of the important aspects of the prophylactic drug treatment of children and adolescents.","journal-title":"Paediatr Drugs"},{"key":"536_CR22","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.pediatrneurol.2010.06.001","volume":"43","author":"K Ahmed","year":"2010","unstructured":"Ahmed K, Oas KH, Mack KJ, Garza I. Experience with botulinum toxin type A in medically intractable pediatric chronic daily headache. Pediatr Neurol. 2010;43:316\u20139.","journal-title":"Pediatr Neurol"},{"key":"536_CR23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1055\/s-0033-1356312","volume":"82","author":"MK Bernhard","year":"2014","unstructured":"Bernhard MK, Bertsche A, Syrbe S, Weise S, Merkenschlager A. Botulinum toxin injections for chronic migraine in adolescents\u2014an early therapeutic option in the transition from neuropaediatrics to neurology. Fortschr Neurol Psychiatr. 2014;82:39\u201342.","journal-title":"Fortschr Neurol Psychiatr"},{"key":"536_CR24","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s11910-012-0251-1","volume":"12","author":"M Kabbouche","year":"2012","unstructured":"Kabbouche M, O'Brien H, Hershey AD. Onabotulinumtoxin A in pediatric chronic daily headache. Curr Neurol Neurosci Rep. 2012;12:114\u20137.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"536_CR25","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1526-4610.2004.04052.x","volume":"44","author":"DW Lewis","year":"2004","unstructured":"Lewis DW, Diamond S, Scott D, Jones V. Prophylactic treatment of pediatric migraine. Headache. 2004;44:230\u20137.","journal-title":"Headache"},{"key":"536_CR26","first-page":"326","volume":"17","author":"HL O'Brien","year":"2015","unstructured":"O'Brien HL, Kabbouche MA, Kacperski J, Hershey AD. Treatment of pediatric migraine. Curr Treat Options Neurol. 2015;17:326. The paper gives an updated overview of the treatment of pediatric migraine.","journal-title":"Curr Treat Options Neurol"},{"key":"536_CR27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/0091270010394852","volume":"52","author":"P Dharmshaktu","year":"2012","unstructured":"Dharmshaktu P, Tayal V, Kalra BS. Efficacy of antidepressants as analgesics: a review. J Clin Pharmacol. 2012;52:6\u201317.","journal-title":"J Clin Pharmacol"},{"key":"536_CR28","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1046\/j.1468-2982.2002.00386.x","volume":"22","author":"SD Silberstein","year":"2002","unstructured":"Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia. 2002;22:491\u2013512.","journal-title":"Cephalalgia"},{"key":"536_CR29","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.pediatrneurol.2014.06.018","volume":"51","author":"A Johnson","year":"2014","unstructured":"Johnson A, Bickel J, Lebel A. Pediatric migraine prescription patterns at a large academic hospital. Pediatr Neurol. 2014;51:706\u201312.","journal-title":"Pediatr Neurol"},{"key":"536_CR30","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.pediatrneurol.2012.03.017","volume":"46","author":"T Eidlitz-Markus","year":"2012","unstructured":"Eidlitz-Markus T, Dlugatch Y, Haimi-Cohen Y, Goldberg-Stern H, Zeharia A. Nonpharmacologic treatment of migraine with low-dose propranolol or amitriptyline. Pediatr Neurol. 2012;46:345\u20139.","journal-title":"Pediatr Neurol"},{"key":"536_CR31","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/head.12105","volume":"53","author":"AD Hershey","year":"2013","unstructured":"Hershey AD, Powers SW, Coffey CS, Eklund DD, Chamberlin LA, Korbee LL, et al. Childhood and adolescent migraine prevention (CHAMP) study: a double-blinded, placebo-controlled, comparative effectiveness study of amitriptyline, topiramate, and placebo in the prevention of childhood and adolescent migraine. Headache. 2013;53:799\u2013816.","journal-title":"Headache"},{"key":"536_CR32","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1590\/1414-431X20143606","volume":"47","author":"A Cayir","year":"2014","unstructured":"Cayir A, Turan MI, Tan H. Effect of vitamin D therapy in addition to amitriptyline on migraine attacks in pediatric patients. Braz J Med Biol Res. 2014;47:349\u201354.","journal-title":"Braz J Med Biol Res"},{"key":"536_CR33","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1001\/jama.2013.282533","volume":"310","author":"SW Powers","year":"2013","unstructured":"Powers SW, Kashikar-Zuck SM, Allen JR, LeCates SL, Slater SK, Zafar M, et al. Cognitive behavioral therapy plus amitriptyline for chronic migraine in children and adolescents: a randomized clinical trial. JAMA. 2013;310:2622\u201330.","journal-title":"JAMA"},{"key":"536_CR34","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1517\/14656566.2012.677434","volume":"13","author":"HL O'Brien","year":"2012","unstructured":"O'Brien HL, Kabbouche MA, Hershey AD. Treating pediatric migraine: an expert opinion. Expert Opin Pharmacother. 2012;13:959\u201366.","journal-title":"Expert Opin Pharmacother"},{"key":"536_CR35","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/ene.12043","volume":"20","author":"MA Leone","year":"2013","unstructured":"Leone MA, Brainin M, Boon P, Pugliatti M, Keindl M, Bassetti CL, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces\u2014revised recommendations 2012. Eur J Neurol. 2013;20:410\u20139.","journal-title":"Eur J Neurol"},{"key":"536_CR36","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","volume":"78","author":"SD Silberstein","year":"2012","unstructured":"Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337\u201345.","journal-title":"Neurology"},{"key":"536_CR37","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/ana.20778","volume":"59","author":"C Ayata","year":"2006","unstructured":"Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol. 2006;59:652\u201361.","journal-title":"Ann Neurol"},{"key":"536_CR38","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1586\/17512433.2014.885835","volume":"7","author":"J Hoffmann","year":"2014","unstructured":"Hoffmann J, Akerman S, Goadsby PJ. Efficacy and mechanism of anticonvulsant drugs in migraine. Expert Rev Clin Pharmacol. 2014;7:191\u2013201.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"536_CR39","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2165\/11316270-000000000-00000","volume":"12","author":"E Bidabadi","year":"2010","unstructured":"Bidabadi E, Mashouf M. A randomized trial of propranolol versus sodium valproate for the prophylaxis of migraine in pediatric patients. Paediatr Drugs. 2010;12:269\u201375.","journal-title":"Paediatr Drugs"},{"key":"536_CR40","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1474-4422(10)70005-3","volume":"9","author":"PJ Goadsby","year":"2010","unstructured":"Goadsby PJ, Sprenger T. Current practice and future directions in the prevention and acute management of migraine. Lancet Neurol. 2010;9:285\u201398.","journal-title":"Lancet Neurol"},{"key":"536_CR41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4137\/JCNSD.S9049","volume":"4","author":"R Shahien","year":"2012","unstructured":"Shahien R, Beiruti K. Preventive agents for migraine: focus on the antiepileptic drugs. J Cent Nerv Syst Dis. 2012;4:37\u201349.","journal-title":"J Cent Nerv Syst Dis"},{"key":"536_CR42","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/jamapediatrics.2013.508","volume":"167","author":"K El-Chammas","year":"2013","unstructured":"El-Chammas K, Keyes J, Thompson N, Vijayakumar J, Becher D, Jackson JL. Pharmacologic treatment of pediatric headaches: a meta-analysis. JAMA Pediatr. 2013;167:250\u20138.","journal-title":"JAMA Pediatr"},{"key":"536_CR43","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4103\/1817-1745.106470","volume":"7","author":"A Abbaskhanian","year":"2012","unstructured":"Abbaskhanian A, Sadeghi HR, Erfani A, Rezai MS. Effective dose of topiramate in pediatric migraine prophylaxis. J Pediatr Neurosci. 2012;7:171\u20134.","journal-title":"J Pediatr Neurosci"},{"key":"536_CR44","first-page":"9","volume":"7","author":"SH Tonekaboni","year":"2013","unstructured":"Tonekaboni SH, Ghazavi A, Fayyazi A, Khajeh A, Taghdiri MM, Abdollah Gorji F, et al. Prophylaxis of childhood migraine: topiramate versus propranolol. Iran J Child Neurol. 2013;7:9\u201314.","journal-title":"Iran J Child Neurol"},{"key":"536_CR45","first-page":"7","volume":"7","author":"R Fallah","year":"2013","unstructured":"Fallah R, Akhavan Karbasi S, Shajari A, Fromandi M. The efficacy and safety of topiramate for prophylaxis of migraine in children. Iran J Child Neurol. 2013;7:7\u201311.","journal-title":"Iran J Child Neurol"},{"key":"536_CR46","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejpn.2012.10.001","volume":"17","author":"H Kim","year":"2013","unstructured":"Kim H, Byun SH, Kim JS, Lim BC, Chae JH, Choi J, et al. Comparison of flunarizine and topiramate for the prophylaxis of pediatric migraines. Eur J Paediatr Neurol. 2013;17:45\u20139.","journal-title":"Eur J Paediatr Neurol"},{"key":"536_CR47","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1177\/1060028014521128","volume":"48","author":"TL Deaton","year":"2014","unstructured":"Deaton TL, Mauro LS. Topiramate for migraine prophylaxis in pediatric patients. Ann Pharmacother. 2014;48:638\u201343.","journal-title":"Ann Pharmacother"},{"key":"536_CR48","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.yebeh.2005.01.002","volume":"6","author":"N Fritz","year":"2005","unstructured":"Fritz N, Glogau S, Hoffmann J, Rademacher M, Elger CE, Helmstaedter C. Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy Behav. 2005;6:373\u201381.","journal-title":"Epilepsy Behav"},{"key":"536_CR49","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3389\/fneur.2013.00192","volume":"4","author":"C Wright","year":"2013","unstructured":"Wright C, Downing J, Mungall D, Khan O, Williams A, Fonkem E, et al. Clinical pharmacology and pharmacokinetics of levetiracetam. Front Neurol. 2013;4:192.","journal-title":"Front Neurol"},{"key":"536_CR50","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1526-4610.2004.04053.x","volume":"44","author":"GS Miller","year":"2004","unstructured":"Miller GS. Efficacy and safety of levetiracetam in pediatric migraine. Headache. 2004;44:238\u201343.","journal-title":"Headache"},{"key":"536_CR51","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1526-4610.2007.00728.x","volume":"47","author":"A Pakalnis","year":"2007","unstructured":"Pakalnis A, Kring D, Meier L. Levetiracetam prophylaxis in pediatric migraine\u2014an open-label study. Headache. 2007;47:427\u201330.","journal-title":"Headache"},{"issue":"Suppl 1","key":"536_CR52","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.seizure.2004.04.016","volume":"13","author":"IE Leppik","year":"2004","unstructured":"Leppik IE. Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004;13 Suppl 1:S5\u20139. discussion S10.","journal-title":"Seizure"},{"key":"536_CR53","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1526-4610.2006.00455.x","volume":"46","author":"A Pakalnis","year":"2006","unstructured":"Pakalnis A, Kring D. Zonisamide prophylaxis in refractory pediatric headache. Headache. 2006;46:804\u20137.","journal-title":"Headache"},{"key":"536_CR54","first-page":"S32","volume":"55","author":"SL Moshe","year":"2000","unstructured":"Moshe SL. Mechanisms of action of anticonvulsant agents. Neurology. 2000;55:S32\u201340. discussion S54-8.","journal-title":"Neurology"},{"issue":"Suppl 1","key":"536_CR55","first-page":"S109","volume":"50","author":"AL Belman","year":"2001","unstructured":"Belman AL, Milazo M, Savatic M. Gabapentin for migraine prophylaxis in children. Ann Neurol. 2001;50 Suppl 1:S109.","journal-title":"Ann Neurol"},{"key":"536_CR56","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1186\/2193-1801-2-573","volume":"2","author":"H Okuma","year":"2013","unstructured":"Okuma H, Iijima K, Yasuda T, Tokuoka K, Kitagawa Y. Preventive effect of cyproheptadine hydrochloride in refractory patients with frequent migraine. Springerplus. 2013;2:573.","journal-title":"Springerplus"},{"key":"536_CR57","doi-asserted-by":"crossref","first-page":"540","DOI":"10.2174\/1871527314666150429114234","volume":"14","author":"J Tajti","year":"2015","unstructured":"Tajti J, Tuka B, Botz B, Helyes Z, Vecsei L. Role of pituitary adenylate cyclase-activating polypeptide in nociception and migraine. CNS Neurol Disord Drug Targets. 2015;14:540\u201353.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"536_CR58","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1177\/0333102413483931","volume":"33","author":"B Tuka","year":"2013","unstructured":"Tuka B, Helyes Z, Markovics A, Bagoly T, Szolcsanyi J, Szabo N, et al. Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients. Cephalalgia. 2013;33:1085\u201395.","journal-title":"Cephalalgia"},{"key":"536_CR59","first-page":"223","volume":"48","author":"BS Rao","year":"2000","unstructured":"Rao BS, Das DG, Taraknath VR, Sarma Y. A double blind controlled study of propranolol and cyproheptadine in migraine prophylaxis. Neurol India. 2000;48:223\u20136.","journal-title":"Neurol India"},{"key":"536_CR60","doi-asserted-by":"crossref","unstructured":"Madani S, Cortes O, Thomas R. Cyproheptadine use in children with functional gastrointestinal disorders. J Pediatr Gastroenterol Nutr. 2015.","DOI":"10.1097\/MPG.0000000000000964"},{"key":"536_CR61","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/brain\/awh298","volume":"128","author":"KG Shields","year":"2005","unstructured":"Shields KG, Goadsby PJ. Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine? Brain. 2005;128:86\u201397.","journal-title":"Brain"},{"key":"536_CR62","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1600-0404.1974.tb01350.x","volume":"50","author":"J Ludvigsson","year":"1974","unstructured":"Ludvigsson J. Propranolol used in prophylaxis of migraine in children. Acta Neurol Scand. 1974;50:109\u201315.","journal-title":"Acta Neurol Scand"},{"key":"536_CR63","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s12098-013-0976-0","volume":"80","author":"R Fallah","year":"2013","unstructured":"Fallah R, Divanizadeh MS, Karimi M, Mirouliaei M, Shamszadeh A. Topiramate and propranolol for prophylaxis of migraine. Indian J Pediatr. 2013;80:920\u20134.","journal-title":"Indian J Pediatr"},{"key":"536_CR64","first-page":"276","volume":"53","author":"M Bakhshandeh Bali","year":"2015","unstructured":"Bakhshandeh Bali M, Rahbarimanesh AA, Sadeghi M, Sedighi M, Karimzadeh P, Ghofrani M. Comparison of propranolol and pregabalin for prophylaxis of childhood migraine: a randomised controlled trial. Acta Med Iran. 2015;53:276\u201380.","journal-title":"Acta Med Iran"},{"key":"536_CR65","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0920-1211(00)00102-9","volume":"40","author":"OE Della Paschoa","year":"2000","unstructured":"Della Paschoa OE, Hoogerkamp A, Edelbroek PM, Voskuyl RA, Danhof M. Pharmacokinetic-pharmacodynamic correlation of lamotrigine, flunarizine, loreclezole, CGP40116 and CGP39551 in the cortical stimulation model. Epilepsy Res. 2000;40:41\u201352.","journal-title":"Epilepsy Res"},{"key":"536_CR66","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1469-8749.2011.04152.x","volume":"54","author":"I Abu-Arafeh","year":"2012","unstructured":"Abu-Arafeh I. Flunarizine for the prevention of migraine\u2014a new look at an old drug. Dev Med Child Neurol. 2012;54:204\u20135.","journal-title":"Dev Med Child Neurol"},{"key":"536_CR67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1468-2982.1988.0801001.x","volume":"8","author":"F Sorge","year":"1988","unstructured":"Sorge F, De Simone R, Marano E, Nolano M, Orefice G, Carrieri P. Flunarizine in prophylaxis of childhood migraine. A double-blind, placebo-controlled, crossover study. Cephalalgia. 1988;8:1\u20136.","journal-title":"Cephalalgia"},{"key":"536_CR68","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1469-8749.2011.04154.x","volume":"54","author":"B Peer Mohamed","year":"2012","unstructured":"Peer Mohamed B, Goadsby PJ, Prabhakar P. Safety and efficacy of flunarizine in childhood migraine: 11 years\u2019 experience, with emphasis on its effect in hemiplegic migraine. Dev Med Child Neurol. 2012;54:274\u20137.","journal-title":"Dev Med Child Neurol"},{"key":"536_CR69","doi-asserted-by":"crossref","first-page":"e484","DOI":"10.1111\/apa.12752","volume":"103","author":"Y Topcu","year":"2014","unstructured":"Topcu Y, Hiz Kurul S, Bayram E, Sozmen K, Yis U. The Paediatric migraine disability assessment score is a useful tool for evaluating prophylactic migraine treatment. Acta Paediatr. 2014;103:e484\u20139.","journal-title":"Acta Paediatr"},{"key":"536_CR70","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","volume":"50","author":"DW Dodick","year":"2010","unstructured":"Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50:921\u201336.","journal-title":"Headache"},{"key":"536_CR71","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jns.2013.05.003","volume":"331","author":"SD Silberstein","year":"2013","unstructured":"Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, et al. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci. 2013;331:48\u201356.","journal-title":"J Neurol Sci"},{"key":"536_CR72","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2165\/11208880-000000000-00000","volume":"72","author":"JE Frampton","year":"2012","unstructured":"Frampton JE. OnabotulinumtoxinA (BOTOX(R)): a review of its use in the prophylaxis of headaches in adults with chronic migraine. Drugs. 2012;72:825\u201345.","journal-title":"Drugs"},{"key":"536_CR73","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0968-0004(02)02177-1","volume":"27","author":"K Turton","year":"2002","unstructured":"Turton K, Chaddock JA, Acharya KR. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem Sci. 2002;27:552\u20138.","journal-title":"Trends Biochem Sci"},{"key":"536_CR74","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.3390\/toxins7072659","volume":"7","author":"D Szok","year":"2015","unstructured":"Szok D, Csati A, Vecsei L, Tajti J. Treatment of chronic migraine with onabotulinumtoxinA: mode of action, efficacy and safety. Toxins (Basel). 2015;7:2659\u201373.","journal-title":"Toxins (Basel)"},{"key":"536_CR75","first-page":"77","volume":"65","author":"J Tajti","year":"2012","unstructured":"Tajti J, Szok D, Tuka B, Csati A, Kuris A, Majlath Z, et al. Botulinum neurotoxin-a therapy in migraine. Ideggyogy Sz. 2012;65:77\u201382.","journal-title":"Ideggyogy Sz"},{"key":"536_CR76","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1177\/0333102413519512","volume":"34","author":"SL Orr","year":"2014","unstructured":"Orr SL, Venkateswaran S. Nutraceuticals in the prophylaxis of pediatric migraine: evidence-based review and recommendations. Cephalalgia. 2014;34:568\u201383.","journal-title":"Cephalalgia"},{"key":"536_CR77","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1526-4610.2005.05044.x","volume":"45","author":"R Pothmann","year":"2005","unstructured":"Pothmann R, Danesch U. Migraine prevention in children and adolescents: results of an open study with a special butterbur root extract. Headache. 2005;45:196\u2013203.","journal-title":"Headache"},{"key":"536_CR78","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ejpain.2007.06.003","volume":"12","author":"R Oelkers-Ax","year":"2008","unstructured":"Oelkers-Ax R, Leins A, Parzer P, Hillecke T, Bolay HV, Fischer J, et al. Butterbur root extract and music therapy in the prevention of childhood migraine: an explorative study. Eur J Pain. 2008;12:301\u201313.","journal-title":"Eur J Pain"}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-015-0536-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11916-015-0536-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-015-0536-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:38:38Z","timestamp":1559435918000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11916-015-0536-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,22]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["536"],"URL":"https:\/\/doi.org\/10.1007\/s11916-015-0536-6","relation":{},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,22]]},"article-number":"1"}}